Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167
administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or
metastatic breast cancer.